Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2018
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NICHE
- 04 Dec 2017 Status changed from suspended to completed.
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 03 Jan 2017 Status changed from recruiting to suspended.